Skip to main content

James Tarver, III, MD

James Tarver, III, MD

Director, Pulmonary Hypertension, Cardiologist

, , , , , , , , , , , , , , , Cardiovascular, ,

Tarver

Overview

Dr. James Tarver is a fellowship-trained, board-certified cardiologist with more than 20 years of experience treating pulmonary hypertension. A graduate of the cardiology fellowship program at the National Naval Medical Center/Walter Reed Army Medical Center in Bethesda, MD, he was named Outstanding Fellow upon completion of his training there. He went on to serve as a pulmonary hypertension Clinical Fellow at Johns Hopkins Hospital. Previously, he earned his medical degree at the Boston University School of Medicine. Dr. Tarver is a veteran of the US Navy, where he served as a medical officer and achieved the rank of Commander. He is a recipient of a Bronze Star and two Gold Star commendations as well as the Navy ACP Governor's Award for Outstanding Clinical Research, among other honors. He has four times been named one of "Orlando's Top Doctors"by Orlando Magazine.

Articles

Long-term results of the DelIVery for Pulmonary Arterial Hypertension trial

PULMONARY CIRCULATION

2019

Education & Training

Education

Boston University; Bethesda Naval Hospital

Residency

Bethesda Naval Hospital

Fellowship

Bethesda Naval Hospital

Board Certifications

American Board of Internal Medicine

Associated Clinical Trials

NCT04732221

INSIGNIA-PAH - A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

Icon for trial | 007-00 INSIGNIA-PAH - A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with Pulmonary Arterial Hypertension

This study is currently enrolling.

This trial is testing MK-5475 in people with pulmonary arterial hypertension (PAH). MK-5475 is still being researched. It has not been approved for use to treat PAH. This trial will compare MK-5475 to a placebo. A placebo looks ...